InvestorsHub Logo
Followers 5
Posts 406
Boards Moderated 0
Alias Born 11/23/2014

Re: midastouch017 post# 1204

Thursday, 10/19/2017 11:49:23 PM

Thursday, October 19, 2017 11:49:23 PM

Post# of 3881
Yes sir it is.

On another note, the Crohn's Disease drug GED-0301 that Celgene acquired from Mongerson for $710M!!! has it's trial discontinued. All I can say is HOLY COW, 700M for a drug that didn't even pass the interim efficacy, so bad in fact that they are discontinuing it. Can you say write off? On the flip side, in 2018 Redhill will have the best performing crohn's treatment data ever released, imo. Expect a deal similar if not bigger than GED-0301 for a drug that actually works, lmao. See below.

http://ir.celgene.com/releasedetail.cfm?ReleaseID=1044647
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent RDHL News